Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLX597
- Development stage
- Preclinical
- Lead developer
- Telix Pharmaceuticals
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TLX597 (also known as TLX597-Tx) is a small-molecule radiopharmaceutical therapy targeting Prostate-Specific Membrane Antigen (PSMA), developed for the treatment of prostate cancer. In-licensed by Telix Pharmaceuticals from the Instituto Nacional de Investigaciones Nucleares (ININ) of Mexico, TLX597 is designed to deliver therapeutic radionuclides, such as Lutetium-177 (^177Lu), directly to cancer cells expressing PSMA. This targeted approach aims to maximize the radiation dose to the tumor while sparing healthy tissues, particularly the salivary and lacrimal glands, which are common sites of off-target uptake for other PSMA-targeting agents. The drug is currently in early-stage development as part of Telix's expanding urology pipeline and represents a next-generation ligand with a potentially improved safety and efficacy profile compared to first-generation small-molecule PSMA agents.
- Other names
- iPSMA
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on TLX597.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLX597.